Cardiovascular disease: Aspirin for primary prevention
DISEASE	INTERVENTION	COMPARISON	RESULTS
Eur Heart J. 2018 Dec 17. doi: 10.1093/eurheartj/ehy813.		Meta-Analysis
IN atherosclerosis, cardiovascular disease, primary prevention, all ages, all patients, diabetic and high cardiovascular risk patients	The Use of aspirin As Prevention, Primary	Is worse Than placebo	To modify all-cause mortality or cardiovascular events (lower incidence of myocardial infarction, but heterogeneous). Conversely, aspirin increased major bleeding (RR 1.5) and intracranial haemorrhage (RR 1.33)
N Engl J Med. 2018 Oct 18;379(16):1499-1508		Randomized Controlled Trial, Multicenter Study
IN atherosclerosis, cardiovascular disease, primary prevention, healthy older patients	The Use of aspirin, 100 mg daily As Prevention, Primary	Is worse Than placebo	To achieve any clinical benefit (composite of death, dementia or persistent physical disability 2.1%/year in both groups) and caused more major bleeding (3.8% aspirin VS 2.8% placebo)
N Engl J Med. 2018 10 18;379(16):1519-1528		Randomized Controlled Trial, Multicenter Study
IN atherosclerosis, cardiovascular disease, primary prevention, healthy older patients	The Use of aspirin, 100 mg daily As Prevention, Primary	Is worse Than placebo	To carry any benefit: it increased all-cause death (1.3 %/year aspirin VS 1.1%/year placebo, p significant), mainly caused by cancer.
N Engl J Med. 2018 Oct 18;379(16):1529-1539. doi: 10.1056/NEJMoa1804988		Randomized Controlled Trial, Multicenter Study
IN atherosclerosis, cardiovascular disease, primary prevention, high risk patients, diabetes mellitus, type 2	The Use of aspirin, 100 mg daily As Treatment, Chronic	Is better Than placebo	To reduce at 7.4 years cardiovascular events (8.5% VS 9.5% placebo), but it increased major bleeding (4% aspirin VS 3% placebo), most of the excess being gastrointestinal bleeding and other extracranial bleeding.